Clinuvel is currently conducting two clinical trials to evaluate the efficacy of SCENESSE® as a combination therapy with narrowband ultraviolet B (NB-UVB) phototherapy compared to NB-UVB alone. The goal of these trials is to determine whether SCENESSE® will reduce the total dose of radiation (NB-UVB) and the time required to reactivate skin pigment producing cells in vitiliginous lesions.
NB-UVB clinically administered thrice per week over 18 months is considered the standard of care in nonsegmental vitiligo to prevent the progression of lesions and stimulate repigmentation in depigmented skin.
To help with the understanding of our vitiligo program, Clinuvel has produced a video explaining its application of SCENESSE® as a repigmentation therapy. The company has also release an in-depth technology update explaining the role of stem cells and NB-UVB therapy repigmentation in vitiligo.
